DT

Disruptive Technologies Innovation Fund

Europe, Dublin, Ireland, Dublin

Description

The Disruptive Technologies Innovation Fund (DTIF) is a significant government initiative in Ireland, established under Project Ireland 2040 and managed by the Department of Enterprise, Trade and Employment. Launched with an initial allocation of €500 million, the fund's primary objective is to drive collaboration between enterprises and research organizations to develop and deploy disruptive technologies. It plays a crucial role in fostering innovation and competitiveness within the Irish economy, targeting areas that have the potential for significant societal and economic impact. The DTIF is not a traditional venture capital fund, but rather a grant-based program designed to co-fund ambitious research, development, and innovation projects.

The fund's investment strategy focuses on projects that are highly innovative, collaborative, and demonstrate a clear pathway to commercialization. It supports consortia comprising at least one enterprise and one research performing organization, encouraging a synergistic approach to technological advancement. The DTIF typically provides grants covering up to 50% of eligible project costs, requiring the remaining funding to be sourced by the consortium members. While the fund's primary focus is on disruptive technologies, it has supported a broad spectrum of sectors, including artificial intelligence, advanced manufacturing, biotechnology, and sustainable solutions, reflecting Ireland's strategic priorities for future growth.

Since its inception, the DTIF has launched multiple calls for proposals, approving a substantial number of high-impact projects. Across its various funding calls, the fund has committed support to over 130 projects, demonstrating its significant reach and commitment to fostering a vibrant innovation ecosystem. Individual project grants typically range from €500,000 to €5,000,000, though larger projects of strategic national importance may be considered for higher funding amounts in exceptional circumstances. This structured approach ensures that funding is directed towards projects with strong potential to deliver tangible economic benefits and position Ireland at the forefront of global technological advancements.

Investor Profile

Disruptive Technologies Innovation Fund has backed more than 28 startups, with 2 new investments in the last 12 months alone. The firm has led 25 rounds, about 89% of its total and boasts 4 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Grant, Series Unknown, Series A rounds (top funding stages).
  • Majority of deals are located in Ireland.
  • Strong thematic focus on Health Care, Medical, Biotechnology.
  • Led 2 rounds in the past year.
  • Typical check size: $540K – $5.4M.

Stage Focus

  • Grant (86%)
  • Series Unknown (7%)
  • Series A (4%)
  • Seed (4%)

Country Focus

  • Ireland (82%)

Industry Focus

  • Health Care
  • Medical
  • Biotechnology
  • Medical Device
  • Artificial Intelligence (Ai)
  • Machine Learning
  • Software
  • Health Diagnostics
  • Pharmaceutical
  • Audio
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Disruptive Technologies Innovation Fund frequently co-invest with?

Faber
Europe, Lisboa, Portugal, Lisbon
Co-Investments: 1
IDA Ireland
North America, New York, United States, New York
Co-Investments: 1
Blue Leaf Ventures
North America, New York, United States, Manhattan
Co-Investments: 1
Elkstone Capital Partners
Europe, Dublin, Ireland, Dublin
Co-Investments: 2
RS Participaties
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
SciFounders
North America, California, United States, San Francisco
Co-Investments: 1
Enterprise Ireland
Europe, Dublin, Ireland, Dublin
Co-Investments: 1
H2
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 1

What are some of recent deals done by Disruptive Technologies Innovation Fund?

AuriGen Medical

Galway, Galway, Ireland

AuriGen Medical is a structural heart and EP company.

Health CareMedicalMedical Device
GrantSep 25, 2025
Amount Raised: $6,300,000
Plio Surgical

Dublin, Dublin, Ireland

Plio Surgical is a firm in the Medical Devices industry.

Health CareManufacturingMedical Device
GrantSep 25, 2025
Amount Raised: $4,583,355
HT Materials Science

Dublin, Dublin, Ireland

HT Materials Science provides nanofluid science in thermal systems for commercial and industrial sector.

Nanotechnology
GrantSep 25, 2025
Amount Raised: $2,703,004
CroíValve

Dublin, Dublin, Ireland

CroíValve is a developed safe, effective, easy to use, percutaneous solution company.

Medical Device
GrantSep 25, 2025
Amount Raised: $8,344,057
ProVascTec

Cork, Cork, Ireland

ProVascTec is a preclinical stage cell treatment firm, to stimulate the development of a novel circulatory system.

BiotechnologyTherapeutics
GrantSep 25, 2025
Amount Raised: $2,938,048
Exergyn

Glasnevin, Dublin, Ireland

Exergyn is a clean-tech company that develops solid state HVAC technology (heat pumps and air conditioning).

CleanTechEnvironmental EngineeringHeating, Ventilation, and Air Conditioning (HVAC)Industrial
GrantSep 25, 2025
Amount Raised: $2,703,004
LaNua Medical

Dublin, Dublin, Ireland

LaNua Medical is a medical device company that develops disruptive image-guided technologies.

Health CareMedicalMedical Device
GrantSep 25, 2025
CardiacBooster

Nijmegen, Gelderland, The Netherlands

CardiacBooster is a medical device company that develops percutaneous left ventricular assist devices.

ManufacturingMedicalMedical Device
Series UnknownAug 7, 2025
Amount Raised: $10,800,000
LIfT BioSciences

London, England, United Kingdom

LIfT Biosciences is a biotech company that develops allogeneic cell therapies using induced pluripotent stem cells.

BiopharmaBiotechnologyHealth CareLife ScienceMedicalOncologyPharmaceutical
GrantJul 29, 2025
Amount Raised: $13,895,193
HAON Life Sciences

Dublin, Dublin, Ireland

HAON Life Sciences is developing innovative cell therapies with primary research targeting a devastating pediatric condition called (HIE).

GrantApr 9, 2025
Amount Raised: $11,711,486